Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : to Present at Upcoming Investor Conference

11/12/2020 | 08:02am EST

Incyte (Nasdaq:INCY) announced today that it will present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020 at 10:30 a.m. EST.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.


© Business Wire 2020
All news about INCYTE CORPORATION
04:55pINSIDER TRENDS : Incyte Sees 90 Days of Insider Buying Trend Scaling Back with S..
MT
01/25INSIDER TRENDS : Merus NV Insider Gets Stock Award, Prolongs Buy Trend
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/21INCYTE : Study of Squamous Cell Carcinoma of Anal Canal Accepted for Priority Re..
MT
01/21INCYTE : Announces Acceptance and Priority Review of BLA for Retifanlimab as a P..
BU
01/19INCYTE : to Report Fourth Quarter and Year-End 2020 Financial Results
BU
01/13BRIACELL THERAPEUTICS : Announces Presentation at the 2021 Keystone Symposia Con..
AQ
01/12MORPHOSYS : Incyte New Drug Application for Potential Lymphoma Treatment Accepte..
MT
01/12PRESS RELEASE : MorphoSys and Incyte Announce -2-
DJ
01/12INCYTE : and MorphoSys Announce Acceptance by Health Canada of the New Drug Subm..
AQ
More news
Financials (USD)
Sales 2020 2 535 M - -
Net income 2020 -334 M - -
Net cash 2020 1 842 M - -
P/E ratio 2020 -61,1x
Yield 2020 -
Capitalization 20 367 M 20 367 M -
EV / Sales 2020 7,31x
EV / Sales 2021 6,28x
Nbr of Employees 1 456
Free-Float 98,7%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 107,06 $
Last Close Price 93,00 $
Spread / Highest target 43,0%
Spread / Average Target 15,1%
Spread / Lowest Target -4,30%
EPS Revisions
Managers and Directors
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION14.27%21 766
MODERNA, INC.49.07%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.-3.44%34 576
SEAGEN INC.-7.11%31 230